Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 186 clinical trials
Featured trial
ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

ACNS0821:Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized

  • 112 views
  • 08 Nov, 2020
  • 1 location
Featured trial
ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children With Refractory, Relapsed or Progressive Neuroblastoma

ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children With Refractory

  • 304 views
  • 08 Nov, 2020
  • 1 location
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

combination with irinotecan-based chemotherapy is to be performed as part of the third-line treatment in patients who showed a response defined according to RECIST 1.1 during the first-line treatment (tumour

aptt
folfiri regimen
serum bilirubin level
adenocarcinoma
liver metastasis
  • 6 views
  • 09 Dec, 2021
  • 1 location
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)

The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse …

  • 0 views
  • 10 May, 2022
  • 21 locations
Irinotecan and Temozolomide for Ewing Sarcoma

The investigators explored the activity of vincristine and irinotecan combined with temozolomide (VIT) in patients with relapsed and metastatic Ewing Sarcoma.

irinotecan
temozolomide
cyclophosphamide
immunosuppressive
metastatic ewing's sarcoma
  • 55 views
  • 28 Feb, 2022
  • 1 location
Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

This is a phase I study to observe the safety and efficacy of irinotecan and bevacizumab combined with re-radiotherapy in the treatment of recurrent glioblastoma. The study will provide a higher

  • 0 views
  • 25 Mar, 2022
  • 1 location
Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors

This Phase I trial will establish the recommended phase II dose of eribulin in combination with fixed doses of oral irinotecan in adolescents and young adults with relapsed or refractory solid

  • 2 views
  • 08 Nov, 2020
  • 1 location
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI)

Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and TAS 102) no longer have treatment options available while maintaining a good performance status which would allow them to receive a new treatment

  • 25 views
  • 03 Feb, 2022
  • 11 locations
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. (INTENSE)

fluorouracil, oxaliplatin and irinotecan preoperatively followed by surgery, and then additionally 4 cycles of the same chemotherapy postoperatively. The standard treatment today is preoperative treatment with

  • 1 views
  • 16 Feb, 2022
  • 4 locations
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

Cancer immunotherapy with immunostimulatory antibodies targeting the CTLA-4 or PD-1/PD-L1 pathways has demonstrated its efficacy in variable proportions of cancer. For metastatic colorectal cancer (mCRC) it appeared that only the small subgroup of patients with MSI-H tumors (microsatellite instability-high phenotype) had a clinically meaningful response to the anti-PD-1- L1 antibodies. …

  • 0 views
  • 26 Jan, 2021
  • 2 locations